TY - JOUR AU - Khan, Dilaram AU - Alam, Fakhre AU - Iltaf, Mohammad AU - Hassan, Muhammad Kamran AU - Khan, Hashmatullah AU - Ghafoor, Amir PY - 2019/03/21 Y2 - 2024/03/29 TI - EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND DACLATASVIR COMBINATION FOR THE TREATMENT OF HEPATITIS C JF - Journal of Postgraduate Medical Institute JA - J Postgrad Med Inst VL - 33 IS - 1 SE - Original Article DO - UR - https://www.jpmi.org.pk/index.php/jpmi/article/view/2291 SP - AB - <p>Objective: To determine the effectiveness and safety of sofosbuvir and daclatsvir combination for the treatment of hepatitis C.</p> <p>Methodology: This study, of 145 patients, was done in the OPDs of Gastroenterology Unit, LRH &amp; HMC of Khyber Pakhtunkhwa, from January 1<sup>st</sup> 2017 to December 1<sup>st</sup>, 2017. HCV infected Patients aged more than 18 years, of either gender, irrespective of previous treatment status having normal hematological tests and ultrasound were included.</p> <p>Results: Ninty three patients (64.13%) were male and 52 (35.86%) female. Mean age was 39.27 ±10.95. Genotype 3 was the most common genotype, present in 130 (89.65%) patients. All patients with HCV Genotype 3, Genotype 2 and Genotype 1 and untypeable had undetectable HCV RNA at week 4, while 122 (93.84%) patients with HCV Genotype 3; 6(85.71%) patients with Genotype 2; and 4(100%) each with Genotype 1 and untypeable had undetectable HCV RNA  twelve weeks after treatment completion. Ten (6.89%) patients developed fatigue, 9(6.20%) patients developed nausea while 8(5.51) patients complained of headache.</p> <p>Conclusion: Combination of sofosbuvir and daclatasvir was found highly effective with high safety profile in HCV infected patients in our set up.</p><p> </p> ER -